- Home
- SUPV vs SLS Comparison
SUPV vs SLS Comparison
Compare SUPV & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SUPV | SLS |
|---|---|---|
| Founded | 1887 | 2012 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 814.9M | 706.7M |
| IPO Year | 2015 | 2007 |
Fundamental Metrics
Financial Performance| Metric | SUPV | SLS |
|---|---|---|
| Price | $9.64 | $4.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $13.00 | $10.00 |
| AVG Volume (30 Days) | 732.0K | ★ 6.2M |
| Earning Date | 05-26-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.04% | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $86.20 | N/A |
| Revenue Next Year | $25.12 | $67.40 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.54 | $1.07 |
| 52 Week High | $17.02 | $6.14 |
Technical Indicators
Market Signals| Indicator | SUPV | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 55.03 | 51.27 |
| Support Level | $9.54 | $4.70 |
| Resistance Level | $11.76 | $5.01 |
| Average True Range (ATR) | 0.58 | 0.42 |
| MACD | 0.18 | -0.06 |
| Stochastic Oscillator | 80.41 | 50.61 |
Price Performance
Historical ComparisonAbout SUPV Grupo Supervielle S.A. each Representing five Class B shares
Grupo Supervielle SA offers financial products & services. The company's segments include Personal and Business Banking, Corporate Banking, Bank Treasury, Consumer Finance, Insurance, and Asset Management and other services. The company provides services to individuals, small businesses, middle-market companies, and large corporates in Argentina. The company also offers mutual fund services.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.